Potential Gene Therapy for Type 2 Gaucher, PR001, Placed on FDA Fast Track
News
The U.S. Food and Drug Administration (FDA) has given fast track designation to PR001, Prevail Therapeutics‘ investigational gene therapy for neuronopathic Gaucher disease. The FDA previously granted the therapy — now in ... Read more